Skip to content
Artwork for Digital Pathology Podcast
Digital Pathology Podcast · May 28 · 46 min

239: The Four Steps Pathology AI Demos Quietly Skip and Why They Matter

Send us Fan Mail What happens when a pathology AI model misses the tissue before it even begins—and can better segmentation, education, and virtual staining close the gaps? In DigiPath Digest #47, I review four recent studies that expose both the promise and the weak points of AI-assisted digital pathology. We start with a step that sounds simple: detecting tissue on a whole slide image. Yet when that first step fails, the downstream algorithm may miss cancer entirely. From there, I look at a practical resource designed to improve communication between pathologists and computational scientists, a self-refining Segment Anything Model that reduces the burden of pixel-perfect nuclear annotations, and a virtual HER2 immunohistochemistry method generated from H&E images. The common lesson? Digital pathology AI is only as reliable as the workflow underneath it. Tissue processing, scanning, segmentation, annotation, model design, and clinical interpretation all matter. Every step needs validation. Discussion highlights 00:00 – Welcome to DigiPath Digest #47 and an overview of the four papers 02:31 – Why tissue detection is the foundation of pathology AI workflows 05:01 – A large prostate pathology study using 33,823 whole slide images for tissue detection and 70,000 images for downstream Gleason grading 06:28 – Classical thresholding missed tissue completely on 118 slides, compared with 24 slides using U-Net++ tissue detection 07:51 – How artifacts and uneven slide color can disrupt classical detection methods 09:59 – AI-based tissue detection reduced total failures by 79% but didn’t eliminate them 10:39 – Why validating only the final algorithm output can hide upstream sources of error 12:05 – Tissue detection choice produced clinically significant differences in final Gleason grade in 3.5% of malignant slides 13:33 – The communication gap between pathology and computer science—and why it still slows progress 15:29 – “Decoding Digital Histopathology” as an accessible guide for computational researchers entering pathology 18:03 – Digital Pathology 101, my free companion resource for anyone starting or continuing a digital pathology journey 20:18 – From collected tissue to glass slide, whole slide image, interpretation, and computational analysis 25:08 – The role of TCGA and the growth of digital pathology datasets across clinical, veterinary, preclinical, and research settings 27:14 – Why pixel-level nuclear annotation remains a bottleneck for deep learning 30:39 – Replacing detailed nuclear outlines with simple point prompts 31:23 – How the self-refining SAM framework uses sparse labels, contrastive learning, and a correction loop 33:25 – Do we really need to keep annotating the same structures for every new model? 37:49 – Generating virtual HER2 IHC from H&E with a score-aware, non-contrastive multitask model 39:53 – Study results: 83.01% accuracy for virtual IHC alone and 97.85% accuracy when H&E and virtual IHC were combined 40:56 – Where virtual IHC may fit as a complementary or triage tool—and why confirmatory testing still matters 44:06 – My perspective on trust, interpretation, and the difference between predicting IHC and predicting molecular alterations 46:17 – Final thoughts and an invitation to continue the discussion Resources mentioned “Impact of Tissue Detection on Diagnostic Artificial Intelligence Algorithms in Prostate Digital Pathology” – Scientific Reports “Decoding Digital Histopathology: The Building Blocks for Computational Researchers” – PLOS Digital Health “Self-Refining Segment Anything Model for Nuclear Segmentation: A Contrastive Learning Approach to Label-Efficient Pathological Imaging” – Diagnostics “HER2 Score-Aware Virtual Immunohistochemistry via Non-Contrastive Multitask Translation” – Diagnostics Digital Pathology 101: All You Need to Know to Start and Continue Your Digital Pathology Journey European Society of Digital and Integrative Pathology The Cancer Genome Atlas (TCGA) If you work in pathology, computational science, image analysis, or AI development, this episode is a useful reminder to look beyond the headline performance metric. The errors that matter may begin much earlier in the workflow. Support the show Get the "Digital Pathology 101" FREE E-book and join us!

0:00-46:45

transcript

No transcript — this publisher did not publish one.

show notes

Send us Fan Mail

What happens when a pathology AI model misses the tissue before it even begins—and can better segmentation, education, and virtual staining close the gaps?

In DigiPath Digest #47, I review four recent studies that expose both the promise and the weak points of AI-assisted digital pathology. We start with a step that sounds simple: detecting tissue on a whole slide image. Yet when that first step fails, the downstream algorithm may miss cancer entirely.

From there, I look at a practical resource designed to improve communication between pathologists and computational scientists, a self-refining Segment Anything Model that reduces the burden of pixel-perfect nuclear annotations, and a virtual HER2 immunohistochemistry method generated from H&E images.

The common lesson? Digital pathology AI is only as reliable as the workflow underneath it. Tissue processing, scanning, segmentation, annotation, model design, and clinical interpretation all matter. Every step needs validation.

Discussion highlights

00:00 – Welcome to DigiPath Digest #47 and an overview of the four papers

02:31 – Why tissue detection is the foundation of pathology AI workflows

05:01 – A large prostate pathology study using 33,823 whole slide images for tissue detection and 70,000 images for downstream Gleason grading

06:28 – Classical thresholding missed tissue completely on 118 slides, compared with 24 slides using U-Net++ tissue detection

07:51 – How artifacts and uneven slide color can disrupt classical detection methods

09:59 – AI-based tissue detection reduced total failures by 79% but didn’t eliminate them

10:39 – Why validating only the final algorithm output can hide upstream sources of error

12:05 – Tissue detection choice produced clinically significant differences in final Gleason grade in 3.5% of malignant slides

13:33 – The communication gap between pathology and computer science—and why it still slows progress

15:29 – “Decoding Digital Histopathology” as an accessible guide for computational researchers entering pathology

18:03 – Digital Pathology 101, my free companion resource for anyone starting or continuing a digital pathology journey

20:18 – From collected tissue to glass slide, whole slide image, interpretation, and computational analysis

25:08 – The role of TCGA and the growth of digital pathology datasets across clinical, veterinary, preclinical, and research settings

27:14 – Why pixel-level nuclear annotation remains a bottleneck for deep learning

30:39 – Replacing detailed nuclear outlines with simple point prompts

31:23 – How the self-refining SAM framework uses sparse labels, contrastive learning, and a correction loop

33:25 – Do we really need to keep annotating the same structures for every new model?

37:49 – Generating virtual HER2 IHC from H&E with a score-aware, non-contrastive multitask model

39:53 – Study results: 83.01% accuracy for virtual IHC alone and 97.85% accuracy when H&E and virtual IHC were combined

40:56 – Where virtual IHC may fit as a complementary or triage tool—and why confirmatory testing still matters

44:06 – My perspective on trust, interpretation, and the difference between predicting IHC and predicting molecular alterations

46:17 – Final thoughts and an invitation to continue the discussion

Resources mentioned

  • “Impact of Tissue Detection on Diagnostic Artificial Intelligence Algorithms in Prostate Digital Pathology” – Scientific Reports
  • “Decoding Digital Histopathology: The Building Blocks for Computational Researchers” – PLOS Digital Health
  • “Self-Refining Segment Anything Model for Nuclear Segmentation: A Contrastive Learning Approach to Label-Efficient Pathological Imaging” – Diagnostics
  • “HER2 Score-Aware Virtual Immunohistochemistry via Non-Contrastive Multitask Translation” – Diagnostics
  • Digital Pathology 101: All You Need to Know to Start and Continue Your Digital Pathology Journey
  • European Society of Digital and Integrative Pathology
  • The Cancer Genome Atlas (TCGA)

If you work in pathology, computational science, image analysis, or AI development, this episode is a useful reminder to look beyond the headline performance metric. The errors that matter may begin much earlier in the workflow.

Support the show

Get the "Digital Pathology 101" FREE E-book and join us!

links3